L. Angelats

发表

Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report

E. Musulen, A. Martínez-Cardús, M. Margelí, 2021 .

Rociletinib-related bilateral cataract

T. Morán, E. Felip, L. Broc, 2018 .

Osimertinib-related skin and mucosal adverse events

A. Boada, E. Carcereny, T. Morán, 2017 .

Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

M. Juan, N. Viñolas, A. Prat, 2023, Cancer Immunology, Immunotherapy.

HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.

C. Perou, J. Parker, M. Dieci, 2022, Journal of the National Cancer Institute.

SAMHD1 expression is a surrogate marker of immune infiltration and determines prognosis after neoadjuvant chemotherapy in early breast cancer

M. Margelí, B. Cirauqui, E. Ballana, 2023, Cellular oncology.

CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition

J. Huppa, F. Brasó-Maristany, S. Guedan, 2024, Nature communications.

Unexpected Durable Complete Response With Anti-PD-L1 Blockade in Metastatic Undifferentiated Pleomorphic Sarcoma: A Case Report With Host and Tumor Biomarker Analysis.

P. Galván, F. Brasó-Maristany, F. Schettini, 2023, JCO precision oncology.

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

N. Viñolas, P. Galván, N. Basté, 2023, Cancer Immunology, Immunotherapy.